Product Code: LUNG(NSCLC)[Plasma]-25
From £285.00
Registration closed: 28/02/2025
Applicable for all labs undertaking molecular testing of cfDNA in plasma for EGFR and KRAS gene variants in NSCLC.
Any molecular test
English
["artificial plasma", "cfDNA", "ctDNA"]
Yes
The scheme is designed to assess the analytical process (genotyping), and reporting (biological and clinical interpretation of the test result) including the overall report layout, content and clerical accuracy.
Participants will receive an individual report including educational advice and a scheme summary report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics which allow participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Three mock clinical cases with matching samples will be provided, 3ml artificial / synthetic plasma is provided per case.
Complete information will be available in scheme instructions.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Restricted to 300 participants, please register early to avoid disappointment. Open to laboratories from ALL countries (note: some restrictions may apply*)
This EQA is supported by an educational grant from AstraZeneca, fees are subsidised so there is a reduced cost for participants. EMQN would like to acknowledge and thank AstraZeneca for this support.
*Sanctions, delivery network exceptions, restrictions on importation etc.
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.